Compare PDO & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDO | NBTX |
|---|---|---|
| Founded | 2020 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 2020 | 2018 |
| Metric | PDO | NBTX |
|---|---|---|
| Price | $11.70 | $34.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $36.00 |
| AVG Volume (30 Days) | ★ 1.1M | 127.0K |
| Earning Date | 01-01-0001 | 03-31-2026 |
| Dividend Yield | ★ 11.80% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $58.17 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.79 | $14.68 |
| 52 Week High | $14.25 | $57.14 |
| Indicator | PDO | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 29.47 | 45.27 |
| Support Level | N/A | $35.59 |
| Resistance Level | $13.23 | $41.99 |
| Average True Range (ATR) | 0.23 | 1.70 |
| MACD | -0.05 | -0.29 |
| Stochastic Oscillator | 0.93 | 32.99 |
PIMCO Dynamic Income Opportunities Fund is a closed-end management investment company. The fund's primary objective is to generate current income, with capital appreciation as a secondary objective. It employs a flexible, multi-sector investment strategy across credit markets, investing in a wide range of income-producing debt securities. The fund actively adjusts allocations to capitalize on opportunities across different economic cycles and market conditions.
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.